Table 3.
Prognostic analyses of clinicopathological parameters in patients with conversion therapy for colorectal liver-limited metastases (n = 52)
| Parameters | HR | Exp (B) | P-value |
|---|---|---|---|
| Disease free survival | |||
| Univariate analysis | |||
| Tumor size > 3 cm | 1.882 | 0.975-3.632 | 0.060 |
| Tumor number ≥ 3 | 1.525 | 0.789-2.945 | 0.209 |
| CEA > 7 ng/mL | 2.795 | 1.388-5.631 | 0.004 |
| RECIST SD or PD | 1.674 | 0.849-3.302 | 0.137 |
| Ki-67 high | 5.608 | 2.382-13.204 | < 0.001 |
| Multivariate analysis | |||
| Ki-67 high | 5.608 | 2.382-13.204 | < 0.001 |
| Overall survival | |||
| Univariate analysis | |||
| Tumor size > 3 cm | 1.825 | 0.656-5.081 | 0.249 |
| Tumor number ≥ 3 | 1.471 | 0.546-3.964 | 0.446 |
| CEA > 7 ng/mL | 2.521 | 0.874-7.275 | 0.087 |
| RECIST SD or PD | 4.355 | 1.569-12.087 | 0.005 |
| Ki-67 high | 6.081 | 1.324-27.934 | 0.02 |
| Multivariate analysis | |||
| RECIST SD or PD | 4.299 | 1.402-12.755 | 0.01 |
| Ki-67 high | 5.366 | 1.084-26.570 | 0.04 |
Cox regression analyses were used. CEA, carcinoembryonic antigen; RECIST, response evaluation criteria in solid tumors (version 1.1).